← 產業報告目錄
Mitochondrial-Based Therapeutics Market Size, Share & Trends Analysis Report By Drug Type (Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs, Corticosteroids), By Indication, By Route of Administration, By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-25頁數 172報告編號 INSIGHTACE-623cf6b076
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 388.2 Mn as of 2023, the global Mitochondrial-Based Therapeutics Market is projected to climb to USD 682.7 Mn by 2031, reflecting a compound annual growth rate of 7.5% over the 2024–2031 period.
Mitochondrial-Based Therapeutics encompasses challenges.
The market's upward path is fueled by growing healthcare spending, technological evolution, and the growing focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and growing investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Mitochondrial-based Therapeutics Market Snapshot
Chapter 4. Global Mitochondrial-based Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Mitochondrial-based Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Mitochondrial-based Therapeutics Industry Trends
Chapter 5. Mitochondrial-based Therapeutics Market Segmentation 1: By Drug Type, Estimates & Trend Analysis
5.1. Market Share by Drug Type, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Type:
5.2.1. Anti-inflammatory Biologics
5.2.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.3. Corticosteroids
Chapter 6. Mitochondrial-based Therapeutics Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Indications:
6.2.1. Mitochondrial Myopathy
6.2.2. Leber's heredity Optic Neuropathy
6.2.3. Leigh Syndrome
6.2.4. Mitochondrial DNA Depletion Syndrome
6.2.5. Mitochondrial Encephalomyopathy
6.2.6. Lactic Acidosis
6.2.7. Myoclonic Epilepsy with ragged red fibres
Chapter 7. Mitochondrial-based Therapeutics Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:
7.2.1. Oral
7.2.2. Intravenous
Chapter 8. Mitochondrial-based Therapeutics Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Drug stores
8.2.4. Online Pharmacies
Chapter 9. Mitochondrial-based Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Mitochondrial-based Therapeutics Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
9.2.3. North America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.2.4. North America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.2.5. North America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.3. Europe
9.3.1. Europe Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
9.3.3. Europe Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.3.4. Europe Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.3.5. Europe Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
9.4.3. Asia Pacific Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.4.4. Asia Pacific Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.4.5. Asia Pacific Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.5. Latin America
9.5.1. Latin America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
9.5.3. Latin America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.5.4. Latin America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.5.5. Latin America Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2024-2031
9.6.3. Middle East & Africa Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.6.4. Middle East & Africa Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.6.5. Middle East & Africa Mitochondrial-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Pfizer Inc.
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Norvartis AG
10.2.3. Takeda Pharmaceuticals
10.2.4. Amgen Inc.
10.2.5. NeuroVive Pharmaceutical AB
10.2.6. Entogene AG
10.2.7. Stealth Biotherapeutics
10.2.8. Ixchel Pharma
10.2.9. Reata Pharmaceuticals
10.2.10. Khondrion BV
10.2.11. Alkeus Pharmaceuticals
10.2.12. Intercept Pharmaceutics
10.2.13. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們